WHO-South Korea biomanufacturing training hub initiative
Moving forward on goal to boost local pharmaceutical production, World Health Organization (WHO) establishes global biomanufacturing training hub in Republic of Korea

Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub.

Learn more ...

Drug shortages and unavailability of medicines
Improving the availability of medicines authorised in the European Union (EU) is a key priority for the European Medicines Agency (EMA) and the European medicines regulatory network. Shortages or other problems with the availability of medicines create challenges for the medicine supply chain, with a potentially serious impact on human and animal health.

Learn more ...

How generics competition helps bring down drug prices
Access to affordable medicines remains a significant public health priority for FDA. The agency regularly conducts economic analyses to measure the impact additional approved generic equivalents can have on consumer generic drug prices. The study below has continually demonstrated that greater competition from generic drugs can help lower drug prices and improve access to drugs for American patients and consumers.

Estimating Cost Savings from New Generic Drug Approvals In 2018, 2019, and 2020

Related articles
WHO revised guidelines for biosimilars: scientific background

Canada calls for support to national pharmacare and generics industry

UK NHS faces drug shortages

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.